U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H30O4S
Molecular Weight 378.525
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TIXOCORTOL

SMILES

[H][C@@]12CC[C@](O)(C(=O)CS)[C@@]1(C)C[C@H](O)[C@@]3([H])[C@@]2([H])CCC4=CC(=O)CC[C@]34C

InChI

InChIKey=YWDBSCORAARPPF-VWUMJDOOSA-N
InChI=1S/C21H30O4S/c1-19-7-5-13(22)9-12(19)3-4-14-15-6-8-21(25,17(24)11-26)20(15,2)10-16(23)18(14)19/h9,14-16,18,23,25-26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1

HIDE SMILES / InChI
Molecular Formula C21H30O4S
Molecular Weight 378.525
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Tixocortol is a synthetic steroid with topical anti-inflammatory properties. In form of Tixocortol pivalate, also known as Pivalone, it is used to treat the inflammatory and allergic manifestations of the rhino-pharynx: allergic rhinitis, acute and chronic congestive rhinitis, vasomotor rhinitis. In addition, it has been shown to be a useful agent for assessing corticosteroid contact dermatitis, particularly for hydrocortisone-type derivatives. Labeled adverse effects are: itchy nose, dryness of the nasal mucosa, edema of the face mucosa, cataract, glaucoma, Cushing syndrome, skin thinning.

Approval Year

1994
149
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2678
PubMed

PubMed

TitleDatePubMed
Concordance of patch test results with four new TRUE test allergens compared with the same allergens from Chemotechnique.
2009 Jan
Positive patch-test reactions to propylene glycol: a retrospective cross-sectional analysis from the North American Contact Dermatitis Group, 1996 to 2006.
2009 Jan-Feb
[Allergic contact dermatitis due to corticosteroids: a 3-year retrospective study in a hospital skin allergy unit].
2009 May
Pattern of corticosteroid allergy in Thailand.
2010 Jul-Aug
Patents

Patents

JP2011518796A
15

Sample Use Guides

In Vivo Use Guide
1 to 2 sprays of 1 % Suspension in each nostril 2 to 4 times daily.
Route of Administration: Nasal
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:56:09 UTC 2023
Edited
by admin
on Fri Dec 15 16:56:09 UTC 2023
Record UNII
ZX3KEK657Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TIXOCORTOL
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
11.BETA.,17-DIHYDROXY-21-MERCAPTOPREGN-4-ENE-3,20-DIONE
Systematic Name English
TIXOCORTOL [VANDF]
Common Name English
tixocortol [INN]
Common Name English
TIXOCORTOL [MI]
Common Name English
CORTISOL 21-THIOL
Common Name English
PROGESTERONE, 11.BETA.,17-DIHYDROXY-21-MERCAPTO-
Common Name English
11.BETA.,17.ALPHA.-DIHYDROXY-21-THIO-3,20-DIOXO-4-PREGNENE
Common Name English
PREGN-4-ENE-3,20-DIONE, 11,17-DIHYDROXY-21-MERCAPTO-, (11.BETA.)-
Systematic Name English
Tixocortol [WHO-DD]
Common Name English
Classification Tree Code System Code
WHO-ATC A07EA05
Created by admin on Fri Dec 15 16:56:10 UTC 2023 , Edited by admin on Fri Dec 15 16:56:10 UTC 2023
WHO-VATC QR01AD57
Created by admin on Fri Dec 15 16:56:10 UTC 2023 , Edited by admin on Fri Dec 15 16:56:10 UTC 2023
WHO-VATC QA07EA05
Created by admin on Fri Dec 15 16:56:10 UTC 2023 , Edited by admin on Fri Dec 15 16:56:10 UTC 2023
WHO-VATC QR01AD07
Created by admin on Fri Dec 15 16:56:10 UTC 2023 , Edited by admin on Fri Dec 15 16:56:10 UTC 2023
NCI_THESAURUS C211
Created by admin on Fri Dec 15 16:56:10 UTC 2023 , Edited by admin on Fri Dec 15 16:56:10 UTC 2023
WHO-ATC R01AD07
Created by admin on Fri Dec 15 16:56:10 UTC 2023 , Edited by admin on Fri Dec 15 16:56:10 UTC 2023
WHO-ATC R01AD57
Created by admin on Fri Dec 15 16:56:10 UTC 2023 , Edited by admin on Fri Dec 15 16:56:10 UTC 2023
Code System Code Type Description
DRUG CENTRAL
4064
Created by admin on Fri Dec 15 16:56:10 UTC 2023 , Edited by admin on Fri Dec 15 16:56:10 UTC 2023
PRIMARY
NCI_THESAURUS
C152667
Created by admin on Fri Dec 15 16:56:10 UTC 2023 , Edited by admin on Fri Dec 15 16:56:10 UTC 2023
PRIMARY
MERCK INDEX
m10911
Created by admin on Fri Dec 15 16:56:10 UTC 2023 , Edited by admin on Fri Dec 15 16:56:10 UTC 2023
PRIMARY Merck Index
RXCUI
57257
Created by admin on Fri Dec 15 16:56:10 UTC 2023 , Edited by admin on Fri Dec 15 16:56:10 UTC 2023
PRIMARY RxNorm
ChEMBL
CHEMBL2107112
Created by admin on Fri Dec 15 16:56:10 UTC 2023 , Edited by admin on Fri Dec 15 16:56:10 UTC 2023
PRIMARY
FDA UNII
ZX3KEK657Z
Created by admin on Fri Dec 15 16:56:10 UTC 2023 , Edited by admin on Fri Dec 15 16:56:10 UTC 2023
PRIMARY
WIKIPEDIA
TIXOCORTOL
Created by admin on Fri Dec 15 16:56:10 UTC 2023 , Edited by admin on Fri Dec 15 16:56:10 UTC 2023
PRIMARY
INN
4125
Created by admin on Fri Dec 15 16:56:10 UTC 2023 , Edited by admin on Fri Dec 15 16:56:10 UTC 2023
PRIMARY
SMS_ID
100000082122
Created by admin on Fri Dec 15 16:56:10 UTC 2023 , Edited by admin on Fri Dec 15 16:56:10 UTC 2023
PRIMARY
CHEBI
63560
Created by admin on Fri Dec 15 16:56:10 UTC 2023 , Edited by admin on Fri Dec 15 16:56:10 UTC 2023
PRIMARY
EPA CompTox
DTXSID30895062
Created by admin on Fri Dec 15 16:56:10 UTC 2023 , Edited by admin on Fri Dec 15 16:56:10 UTC 2023
PRIMARY
PUBCHEM
162955
Created by admin on Fri Dec 15 16:56:10 UTC 2023 , Edited by admin on Fri Dec 15 16:56:10 UTC 2023
PRIMARY
EVMPD
SUB11127MIG
Created by admin on Fri Dec 15 16:56:10 UTC 2023 , Edited by admin on Fri Dec 15 16:56:10 UTC 2023
PRIMARY
DAILYMED
ZX3KEK657Z
Created by admin on Fri Dec 15 16:56:10 UTC 2023 , Edited by admin on Fri Dec 15 16:56:10 UTC 2023
PRIMARY
MESH
C040971
Created by admin on Fri Dec 15 16:56:10 UTC 2023 , Edited by admin on Fri Dec 15 16:56:10 UTC 2023
PRIMARY
DRUG BANK
DB09091
Created by admin on Fri Dec 15 16:56:10 UTC 2023 , Edited by admin on Fri Dec 15 16:56:10 UTC 2023
PRIMARY
CAS
61951-99-3
Created by admin on Fri Dec 15 16:56:10 UTC 2023 , Edited by admin on Fri Dec 15 16:56:10 UTC 2023
PRIMARY
Related Record Type Details
Structure of TIXOCORTOL
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966